Free Trial
NASDAQ:ZYME

Zymeworks (ZYME) Stock Price, News & Analysis

Zymeworks logo
$17.23 +0.63 (+3.80%)
As of 09/29/2025 04:00 PM Eastern

About Zymeworks Stock (NASDAQ:ZYME)

Advanced

Key Stats

Today's Range
$16.74
$17.60
50-Day Range
$12.02
$17.23
52-Week Range
$9.03
$17.70
Volume
555,484 shs
Average Volume
558,732 shs
Market Capitalization
$1.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Zymeworks Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
0th Percentile Overall Score

ZYME MarketRank™: 

Zymeworks scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Zymeworks.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zymeworks is -17.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zymeworks is -17.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Zymeworks has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.45% of the float of Zymeworks has been sold short.
  • Short Interest Ratio / Days to Cover

    Zymeworks has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Zymeworks has recently increased by 1.17%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Zymeworks does not currently pay a dividend.

  • Dividend Growth

    Zymeworks does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.45% of the float of Zymeworks has been sold short.
  • Short Interest Ratio / Days to Cover

    Zymeworks has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Zymeworks has recently increased by 1.17%, indicating that investor sentiment is decreasing.
  • Search Interest

    Only 2 people have searched for ZYME on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zymeworks insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.92% of the stock of Zymeworks is held by insiders.

  • Percentage Held by Institutions

    92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Zymeworks' insider trading history.
Receive ZYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZYME Stock News Headlines

Zymeworks down after dropping anticancer agent
Defense Billions Flow Into Critical Minerals — Here’s Why Gold’s Key
What do missile defense systems and gold miners have in common? More than most investors realize. The United States has committed $175 billion to secure North America's skies. At the center of this push: the Golden Dome, a next-generation missile defense shield. That's where one explorer enters the story.tc pixel
See More Headlines

ZYME Stock Analysis - Frequently Asked Questions

Zymeworks' stock was trading at $13.33 at the start of the year. Since then, ZYME stock has increased by 29.3% and is now trading at $17.23.

Zymeworks Inc. (NASDAQ:ZYME) released its quarterly earnings data on Thursday, August, 7th. The company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.55. The business earned $48.73 million during the quarter, compared to analyst estimates of $13.66 million. Zymeworks had a negative net margin of 59.96% and a negative trailing twelve-month return on equity of 21.59%.

Zymeworks (ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/07/2025
Today
9/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ZYME
Previous Symbol
NASDAQ:ZYME
CIK
1937653
Web
N/A
Employees
460
Year Founded
2003

Profitability

EPS (Trailing Twelve Months)
($0.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$122.69 million
Net Margins
-59.96%
Pretax Margin
-54.88%
Return on Equity
-21.59%
Return on Assets
-16.52%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.69
Quick Ratio
7.69

Sales & Book Value

Annual Sales
$76.30 million
Price / Sales
16.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.92 per share
Price / Book
3.50

Miscellaneous

Outstanding Shares
75,170,000
Free Float
73,723,000
Market Cap
$1.30 billion
Optionable
N/A
Beta
1.27

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:ZYME) was last updated on 9/30/2025 by MarketBeat.com Staff
From Our Partners